Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety Study of Prucalopride for the Treatment of Elderly Patients With Chronic Constipation

This study has been completed.
Information provided by:
Movetis Identifier:
First received: June 14, 2007
Last updated: May 28, 2008
Last verified: June 2007

The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of chronic constipation in elderly patients.


Prucalopride 2 mg and 4 mg given once daily for 12 weeks is superior to placebo for the treatment of patients with chronic constipation and is well tolerated in those patients

Condition Intervention Phase
Drug: prucalopride
Drug: Prucalopride
Other: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Quality-of-Life of R108512 Tablets in Elderly Subjects With Chronic Constipation

Resource links provided by NLM:

Further study details as provided by Movetis:

Primary Outcome Measures:
  • Proportion of subjects with an average of 3 or more SCBM per week [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Secondary efficacy variables: 1)Symptom variables 2)QOL variables [ Time Frame: 12 weeks ]

Enrollment: 303
Study Start Date: October 1998
Study Completion Date: September 1999
Primary Completion Date: September 1999 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Drug: prucalopride
2 mg o.d.
Other Name: Resolor
Active Comparator: 2
Drug: Prucalopride
4 mg o.d.
Other Name: Resolor
Placebo Comparator: 3
Other: Placebo

Detailed Description:

This is a multicentre, randomised, Phase III trial with a parallel-group design, consisting of a 2 week drug-free run-in period, followed by a 4-week, double-blind, placebo-controlled treatment period.

During the run-in period, the subject's bowel habit will be documented and the existence of constipation confirmed. At the start of this period, all existing laxative medication will be withdrawn and subjects will be instructed not to change their diet or lifestyle during the trial.

Subjects will be allowed to take a laxative (Dulcolax®) as a rescue medication throughout the trial, but only if they have not had a bowel movement for three or more consecutive days. Subjects will enter the double-blind period if constipation is shown to be present during the run-in period. Patients will be randomly allocated to one of the 4 treatment arms: 1 mg, 2 mg, 4 mg of R108512 or placebo, with a 25% chance to each treatment group.

During the double-blind period, subjects will be treated for 4 weeks with either 1 mg, 2 mg or 4 mg R108512 or placebo, given once daily before breakfast.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female subjects of 65 or over 65 years of age.
  2. History of constipation; the subject reports, on average, two or fewer spontaneous bowel movements per week that result in a feeling of complete evacuation and one or more of the following for at least 6 months before the selection visit:

    1. very hard (little balls) and/or hard stools at least a quarter of the stools
    2. sensation of incomplete evacuation following at least a quarter of the stools
    3. straining at defecation at least a quarter of the stools. The above criteria are only applicable for spontaneous bowel movements, i.e., not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.

Subjects who never have spontaneous bowel movements are considered to be constipated and are eligible for the trial.

Exclusion Criteria:

  1. Subjects in whom constipation is thought to be drug-induced, or subjects using any disallowed medication.
  2. Subjects suffering from endocrine disorders, metabolic disorders or neurologic disorders.
  3. Subjects with the main complaint of abdominal pain.
  4. Subjects with a known megacolon/megarectum or a diagnosis of pseudo-obstruction.
  5. Constipation as a result of surgery.
  6. Known or suspected organic disorders of the large bowel, i.e. obstruction, carcinoma, or inflammatory bowel disease.
  7. Malignancies or AIDS.
  8. Known serious illnesses: clinically significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric or metabolic disturbances. Patients with known diverticulosis may be included.
  9. Subjects with a serum creatinine concentration > 2 mg/dL (> 180 micromol/L).
  10. Subjects with clinically significant abnormalities of haematology, urinalysis, or blood chemistry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00487422

Sponsors and Collaborators
Principal Investigator: Gerald Demschik, M.D. Geriatriezentrum am Wienerwald
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Renate Specht Gryp, Movetis Identifier: NCT00487422     History of Changes
Other Study ID Numbers: PRU-INT-12
Study First Received: June 14, 2007
Last Updated: May 28, 2008

Keywords provided by Movetis:

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms processed this record on April 24, 2017